Theranostic Approach by Early Multigene Sequencing in Advanced Poor Prognosis Cancers

The European Society for Medical Oncology (ESMO) strongly recommends to develop multigene sequencing in the framework of molecular screening programmes, in order to improve access to innovative drugs and to accelerate clinical research in cancers. * Accordingly, this project aims to study the contribution of early systematic multigene sequencing (NGS) discussed in Molecular Tumour Board for poor prognosis cancers, with no current indication for early sequencing. * The investigators teams propose to perform a randomized study in tumours in which actionable therapeutic targets according to the ESMO ESCAT scale are known (ESCAT II/IV) especially in pancreatic ductal adenocarcinoma, hepatocellular carcinoma or triple negative breast cancer. Two approaches will be compared: a large multigenic early sequencing approach since the first line setting versus a Plan France Medecine Genomique 2025 approach since the second line setting. The frequency of really initiated therapeutic proposals according to the molecular status will be compared in each group.

NCT Number	NCT06958224
Lead Sponsor	University Hospital, Lille
Conditions	Breast Cancer, Liver Cancer, Pancreatic Ductal Adenocarcinoma
Enrollment	360 participants
Start Date	2026-04-10
Primary Completion	2028-11-10 (estimated)
Study Completion	2029-01-09 (estimated)
Updated on ClinicalTrials.gov	2026-02-20